.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 3,875,149

« Back to Dashboard

Details for Patent: 3,875,149

Title: Oximes of 1-(ortho-acyl-phenoxy)-2-hydroxy-3-aminopropanes
Abstract:Oximes of the formula: ##SPC1## Wherein R is hydrogen or phenyl, R.sub.1 is hydrogen, alkyl of up to 6 carbon atoms, or hydroxyalkyl of up to 6 carbon atoms, R.sub.2 is alkyl of up to 6 carbon atoms, or hydroxyalkyl of up to 6 carbon atoms, or R.sub.1 and R.sub.2 together with the nitrogen to which they are attached represent morpholino, R.sub.3 is hydrogen, or alkyl of up to 6 carbon atoms, and R.sub.5 is hydrogen or phenylalkyl of up to 6 carbon atoms in the alkyl residue, and non-toxic acid addition salts thereof, possess pharmacodynamic properties of value in the treatment of prophylaxis of various cardiac disorders, especially cardiac arrhythmias.
Inventor(s): Wooldridge; Kenneth Robert Harry (Brentwood, EN), Basil; Berkeley (Highwood near Chelmsford, EN)
Assignee: May & Baker Limited (EN)
Filing Date:Dec 19, 1972
Application Number:05/316,508
Claims:1. An oxime of the formula: ##SPC15##

wherein R is hydrogen or phenyl, R.sub.1 is hydrogen, alkyl of up to 6 carbon atoms, or hydroxyalkyl of up to 6 carbon atoms, R.sub.2 is alkyl of up to 6 carbon atoms or hydroxyalkyl of up to 6 carbon atoms, or R.sub.1 and R.sub.2 together with the nitrogen to which they are attached represent morpholino, R.sub.3 is hydrogen or alkyl of up to 6 carbon atoms, and R.sub.5 is hydrogen or phenylalkyl of up to 6 carbon atoms in the alkyl residue, and non-toxic acid addition salts thereof.

2. An oxime according to claim 1 wherein R.sub.1 and R.sub.2 are both methyl, or propyl or 2-hydroxyethyl, R.sub.3 is hydrogen and R.sub.5 is benzyl, and non-toxic acid addition salts thereof.

3. An oxime according to claim 1 selected from the class consisting of DL-1-(o-acetylphenoxy)-2-hydroxy-3-isopropylaminopropane O-benzyloxime, and non-toxic acid addition salts thereof.

4. An oxime according to claim 1 selected from class consisting of DL-1-(o-formylphenoxy)-2-hydroxy-3-isopropylaminopropane O-benzyloxime, and non-toxic acid addition salts thereof.

5. An oxime according to claim 1 selected from the class consisting of DL-1-(o-formylphenoxy)-2-hydroxy-3-morpholinopropane O-benzyloxime, and non-toxic acid addition salts thereof.

6. An oxime according to claim 1 selected from the class consisting of DL-1-(o-acetylphenoxy)-2-hydroxy-3-morpholinopropane O-benzyloxime, and non-toxic acid addition salts thereof.

7. An oxime according to claim 1 selected from the class consisting of DL-1-(o-formylphenoxy)-2-hydroxy-3-diethylaminopropane O-benzyloxime, and non-toxic acid addition salts thereof.

8. An oxime according to claim 1 selected from the class consisting of DL-1-(o-acetylphenoxy)-2-hydroxy-3-diethylaminopropane oxime, and non-toxic acid addition salts thereof.

9. An oxime according to claim 1 selected from the class consisting of DL-1-(o-formylphenoxy)-2-hydroxy-3-dimethylaminopropane O-benzyloxime, and non-toxic acid addition salts thereof.

10. An oxime according to claim 1 selected from the class consisting of DL-1-(o-formylphenoxy)-2-hydroxy-3-di-n-propylaminopropane O-benzyloxime, and non-toxic acid addition salts thereof.

11. An oxime according to claim 1 selected from the class consisting of DL-1-(o-formylphenoxy)-2-hydroxy-3-di(2-hydroxyethyl)aminopropane O-benzyloxime and non-toxic acid addition salts thereof.

12. An oxime according to claim 1 selected from the class consisting of DL-1-(2-acetyl-4-phenylphenoxy)-2-hydroxy-3-isopropylaminopropane oxime and non-toxic acid addition salts thereof.

13. An oxime according to claim 1 wherein R is hydrogen, R.sub.1 and R.sub.2 are both methyl, ethyl or n-propyl, or one of R.sub.1 and R.sub.2 is hydrogen and the other is isopropyl, or R.sub.1 and R.sub.2 together with the nitrogen to which they are attached represent morpholino, R.sub.3 is hydrogen or methyl, and R.sub.5 is hydrogen or benzyl, and non-toxic acid addition salts thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc